Effect of allopurinol in treatment of acute lymphoblastic lukemia

Evaluation of effect of oral allopurinol in preventing elevated liver enzyme level in chilhood acute lymphoblastic leukemia in maintenance therapy phase

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240702062309N1

Enrollment

Registered

2025-03-04

Start date

2022-09-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic lukemia. Acute lymphoblastic leukemia [ALL]

Interventions

Intervention 1: The control group (group A) is 25 people who are treated with mercaptopurine tablets according to the standard treatment protocol (based on the same dose they have already received) an

Eligibility

Sex/Gender

All

Age

1 Days to 18 Years

Inclusion criteria

Inclusion criteria: All childen with ALL in maintenance phase of drug therapy

Exclusion criteria

Exclusion criteria: Severe myelo suppression after allopurinol use(Absolute neutrophil count less than 100) History of severe allergy to drug allopurinol History of any underlying liver disease unrelated to chemotherapy drug disase

Design outcomes

Primary

Measure	Time frame
Liver enzyme. Timepoint: 0, 14, 30, 60, 90, 120, 150 and 180 days after study starts. Method of measurement: Laboratory tests.	—

Secondary

Measure	Time frame
Absolute neutrophil count. Timepoint: 0, 14, 30, 60, 90, 120, 150 and 180 days after study starts. Method of measurement: blood labratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohre Jali

Shahid Beheshti University of Medical Sciences

Dr.z.jali@irct.ir+98 21 6659 3757

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026